Article

Cost and cost-effectiveness of alternative screening and diagnostic pathways for achieving hepatitis C elimination in the country of Georgia

2025-05-23

Abstract excerpt

<h4>Background</h4> We evaluated the cost and cost-effectiveness of alternative screening pathways during 2018–2022 within Georgia’s hepatitis C elimination program, which started in 2015. <h4>Methods</h4> We calculated patient-level costs (2022 USD$) of hepatitis C treatment with centralized and decentralized diagnostic testing in hospitals, primary healthcare (PHC), harm reduction providers (HRP), or specialized...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7e927e5c-5e78-5162-a55d-c306d2bdb3fe
DOI: 10.1101/2025.05.22.25327932

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cost and cost-effectiveness of alternative screening and diagnostic pathways for achieving hepatitis C elimination in the country of GeorgiaDOI 10.1101/2025.05.22.25327932Read

Cost and cost-effectiveness of Hepatitis C virus self-testing in four settings: an economic evaluationSemantic proximity Read

Interim impact evaluation of the hepatitis C virus elimination program in GeorgiaSemantic proximity Read

The Cost-effectiveness of One-step Point-of-care Hepatitis C Virus RNA Testing in the United StatesSemantic proximity Read

Hepatitis C Core Antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysisSemantic proximity Read

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read

Real-World Impact of a Simplified 'Test and Treat' Strategy for In-Hospital HCV Micro-Elimination.Semantic proximity Read

Cost-effectiveness and population outcomes of general population screening for hepatitis C.Semantic proximity Read

Cost effectiveness of hepatitis C direct acting agents.Semantic proximity Read

Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.Semantic proximity Read

Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.Semantic proximity Read

Assessing the potential cost-effectiveness of centralized vs point-of-care testing for hepatitis C virus in Pakistan: a model-based comparisonSemantic proximity Read

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.Semantic proximity Read